Результаты поиска

Translational Clinical Strategies for the Prevention of Gastrointestinal Tract Graft Versus Host Disease.

Graft versus host disease (GVHD) is the major non-relapse complication associated with allogeneic hematopoietic stem cell transplantation (HSCT). Unfortunately, GVHD occurs in roughly half of patients following this therapy and can induce severe life-threatening side effects and premature mortality. The pathophysiology of GVHD is driven by alloreactive donor T cells that induce a proinflammatory environment to cause pathological damage in the skin, gastrointestinal (GI) tract, lung, and liver during the acute phase of this disease. Recent work has demonstrated that the GI tract is a pivotal ta

Совпадение в полном тексте источника
… Administration of infliximab, a chimeric IgG1 monoclonal antibody which binds to soluble and transmembrane human TNF-α, has been given to patients for GVHD treatment with some success ( 36 ), but there is limited clinical data on the efficacy of infliximab for GVHD prophylaxis, particularly in the GI … Hamadani et al. conducted a prospective trial of infliximab for the prophylaxis of GVHD ( 37 ). Infliximab or placebo was administered one day prior to conditioning, but unfortunately treated patients exhibited similar incidences of grade II-IV acute GVHD compared to the control group (both ~36%). …

A Continuous Registry of Medical Record, Patient Input, and Epidemiological Data of Patients With Ulcerative Colitis: a Multicentre, Prospective, Observational Clinical Registry Study in Japan.

BackgroundThis registry aims to allow for a prospective non-interventional observational study of ulcerative colitis. This will facilitate monitoring of the current state of ulcerative colitis in Japan and improving the long-term disease course and adverse events associated with current treatment options.MethodsInclusion of patients from five centres in Japan is planned. The study is expected to take place from July 15, 2020, to November 30, 2024. Background, demographics, and medical history/information will be collected from electronic medical records at enrolment. Medical information includ

Совпадение в полном тексте источника
… The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients. Am J Gastroenterol 2007;102:794–802. 29. Panaccione R, Ghosh S, Middleton S, Márquez JR, Scott BB, Flint L, et al. … Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology 2014;146:392–400.e3. 30. Panés J, Su C, Bushmakin AG, Cappelleri JC, Mamolo C, Healey P. …

Clinical utility of ustekinumab in Crohn's disease.

The introduction of anti-tumor necrosis factor (TNF) therapy marked an important milestone in the management of moderate-to-severe Crohn's disease (CD). However, there remains a pressing demand for alternative therapeutic options for patients with primary nonresponse, secondary loss of response, or intolerable side effects to conventional treatment and TNF antagonists. Ustekinumab (UST) is a fully human IgG1κ monoclonal antibody that inhibits the p40 subunit shared by the proinflammatory cytokines, the interleukin (IL)-12 and -23. This blockade leads to dampening of the inflammatory cascade an

Совпадение в полном тексте источника
… The first class of biological agents approved for the management of CD were tumor necrosis factor (TNF) alpha inhibitors, including infliximab (IFX), adalimumab (ADA), and certolizumab pegol (CZP). 4 – 8 The introduction of anti-TNF agents was revolutionary for the management of CD due to their remarkable … for Crohn’s disease: the ACCENT I randomised trial Lancet 2002 359 9317 1541 1549 12047962 10.1016/S0140-6736(02)08512-4 5 Sands BE Anderson FH Bernstein CN Infliximab maintenance therapy for fistulizing Crohn’s disease N Engl J Med 2004 350 9 876 885 14985485 10.1056/NEJMoa030815 6 Colombel JF Sandborn …

UEG Week 2017 Oral Presentations

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… We included randomized controlled trials in adults with moderate to severe UC that compared infliximab, adalimumab, golimumab, vedolizumab and tofacitinib to each other or placebo. … However, only infliximab (MD18.58; 95%CI 13.19 to 23.97) and vedolizumab (MD 18.00; 95%CI 11.08 to 24.92) achieved a clinically meaningful improvement in HRQL, with an increase in IBDQ score of more than 16 points. …

A prospective phase 2 clinical trial of a C5a complement inhibitor for acute GVHD with lower GI tract involvement.

Involvement of lower gastrointestinal tract (LGI) occurs in 60% of patients with graft-versus-host-disease (GVHD). Complement components C3 and C5 are involved in GVHD pathogenesis. In this phase 2a study, we evaluated the safety and efficacy of ALXN1007, a monoclonal antibody against C5a, in patients with newly diagnosed LGI acute GVHD receiving concomitant corticosteroid. Twenty-five patients were enrolled; one was excluded from the efficacy analysis based upon negative biopsy. Most patients (16/25, 64%) had acute leukemia; 52% (13/25) had an HLA-matched unrelated donor; and 68% (17/25) rece

Совпадение в полном тексте источника
… A phase III study of infliximab and corticosteroids for the initial treatment of acute graft-versus-host disease. Biol Blood Marrow Transpl. 2009;15:1555–62. doi: 10.1016/j.bbmt.2009.08.003. 13. Cragg L, Blazar BR, Defor T, Kolatker N, Miller W, Kersey J, et al. … Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis. Int J Clin Pharm Ther. 2010;48:297–308. doi: 10.5414/CPP48297. 34. Chaudhury C, Brooks CL, Carter DC, Robinson JM, Anderson CL. …

Immune checkpoint inhibitors in cancer therapy: Review of orofacial adverse events and role of the oral healthcare provider.

Immune checkpoint inhibitors (ICIs) are a revolutionary class of antineoplastic therapy that restore anti-tumor immunity. Consequences of this enhanced immune response include a multitude of immune related adverse events (irAEs) that can affect any body system, including the mouth. Orofacial irAEs reproduce features of numerous immune-mediated conditions, including oral lichen planus, mucous membrane pemphigoid, and Sjögren syndrome, among others. The aim of this review is to summarize known orofacial irAEs and to familiarize oral healthcare providers with how to identify and manage these toxi

Совпадение в полном тексте источника
… Corticosteroids are a mainstay of treatment for irAEs, though steroid-sparing, reaction-specific regimens (e.g., mycophenolate mofetil, infliximab, hydroxychloroquine) are being increasingly utilized [ 3 , 6 , 12 ]. … Steroid-sparing immunosuppressive agents can also be considered, such as doxycycline, mycophenolate mofetil, acitretin, infliximab, dupilumab, or IVIG [ 6 ]. …

Early intervention in the treatment of rheumatoid arthritis: focus on tocilizumab.

Tocilizumab is a fully humanized monoclonal antibody against interleukin-6 receptors that was approved for the treatment of patients with rheumatoid arthritis (RA). Several lines of evidence, obtained both from conventional disease-modifying anti-rheumatic drugs (DMARDs) and tumor necrosis factor (TNF) inhibitors, have supported the concept of "window of opportunity" as showing that these therapies consistently work better in early disease as compared to established RA. This review addresses the question of whether a window of opportunity gained with conventional DMARDs and TNF inhibitors can

Совпадение в полном тексте источника
… Role of infliximab in the treatment of early rheumatoid arthritis. Clin Exp Rheumatol. 2003;21(5 Suppl 31):200–202. 11. Yazici Y, McMorris BJ, Darkow T, Rosenblatt LC. … Patient and physician perception of the infusion process of the biologic agents abatacept, infliximab, and rituximab for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2009;27:907–913. 12. Aletaha D, Eberl G, Nell VP, Machold KP, Smolen JS. …

Adverse Events of Oncologic Immunotherapy and Their Management.

Over the past two decades, immunotherapy has emerged as a promising treatment option for patients with cancer. However, newer versions of immunotherapy, such as checkpoint inhibitors, may be associated with unusual adverse effects (AEs) that can range in severity from mild to life-threatening. Unlike common AEs of conventional chemotherapy, which have a predictable nadir or cyclic pattern after administration, AEs of these newer immunotherapies are variable, depending on the type of immunotherapy, route of administration, and mechanism of action. The onset and resolution of these AEs may be pr

Совпадение в полном тексте источника
… If refractory to infliximab, consider vedolizumab Grade 3- Discontinue anti-CTLA-4, consider resuming anti-PD1/anti-PD-L1 after symptoms have resolved. Consider Gastrointestinal referral Grade 4- Discontinue treatment permanently, hospitalization Endocrine irAEs Thyroid 1. … For patients with grade 3 irAEs, the checkpoint inhibitor should be placed on hold and high-dose corticosteroids should be administered and tapered over 4–6 weeks; if symptoms do not improve within 48–72 h, administer infliximab; however, if symptoms and/or laboratory values return to grade 1 or less …

Integrating imaging and biomarker assessment to better define psoriatic arthritis and predict response to biologic therapy.

The treatment options for PsA have substantially expanded over the last decade. Approximately 40% of patients will not respond to first-line anti-TNF-α therapies. There is limited data to help clinicians select the most appropriate biologic therapy for PsA patients, including guidance for decisions on biologic therapy switching. In this review we will examine the current understanding of predictors of response to treatment. Imaging technology has evolved to allow us to better study psoriatic disease and define disease activity, including synovitis and enthesitis. Enthesitis is implicated in th

Совпадение в полном тексте источника
… Efficacy of infliximab on MRI-determined bone oedema in psoriatic arthritis. Ann Rheum Dis 2007;66:778–81. 57. Kampylafka E, d’Oliveira I, Linz C. et al. … Short-term infliximab therapy improves symptoms of psoriatic arthritis and decreases concentrations of cartilage oligomeric matrix protein. J Clin Pharm Ther 2006;31:149–52. 111. Grazio S, Razdorov G, Erjavec I. et al. …

Is Prophylaxis the Only Way Out for Cytokine Release Syndrome Associated With Chimeric Antigen T-cell Therapy?

Chimeric antigen receptor T-cell (CAR-T) therapy is a new advancement in hematology and oncology with its use in treating many refractory malignancies. Cytokine release syndrome (CRS) is CAR-T's clinically hazardous side effect, ranging from mild to life-threatening events. It was one of the first side effects detected with CAR-T. We conducted a literature review using PubMed (MeSH) to study CRS incidence after the administration of CAR-T to reflect its clinical importance. Nine studies are mentioned, with a total of 1357 patients enrolled for different types of refractory/relapsed cancers, an

Совпадение в полном тексте источника
… Infliximab, Anakinra, and Siltuximab Studies by Lee et al. show the use of anakinra and infliximab, IL-1 R inhibitor and anti-TNF-alpha antibodies, respectively, in CRS due to other causes [ 25 ]. …

Clinical and epidemiological features of ulcerative colitis patients in Sardinia, Italy: Results from a multicenter study.

BACKGROUND: There are little data on the epidemiological and clinical features of adult patients with ulcerative colitis (UC) in the different Italian regions, mainly derived from the absence of a national registry. This prevents correct interpretation of the disease burden. AIM: To assess the main clinical and epidemiological features of adult patients diagnosed with UC in Sardinia, Italy. METHODS: We performed a multicenter, observational, cross-sectional study that included adult patients with UC enrolled in seven gastroenterology unit centers in Sardinia. Data were obtained from the pati

Совпадение в полном тексте источника
… At study inclusion, infliximab was the most common anti-tumor necrosis factor alpha (TNFα) biologic used, (55/442, 12.4%), followed by adalimumab (12/442, 2.7%) and golimumab (5, 1.1%); while vedolizumab (VDZ) was used in 11 (2.5%) patients. … Four patients (7.8%) were under treatment with biologic agent: three with infliximab and one with VDZ. No one underwent colectomy. …

ESCP 36th European Symposium on Clinical Pharmacy ‘Implementing Clinical Pharmacy in Community and Hospital Settings: Sharing the Experience’, Istanbul, Turkey 25–27 October 2007; Abstracts

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… a meta-analysis PT-150 An evaluation of systemic and topical treatments of otitis media: a hospital study in Turkey PT-152 Antineoplastic chemotherapies monitoring: sampling method optimization PT-158 Audit of cardiovascular risk management in diabetic outpatients in Kuwait PT-180 Pediatric use of infliximab …

Intravenous immunoglobulin for the treatment of Kawasaki disease.

BACKGROUND: Kawasaki disease (KD) is an acute systemic vasculitis (inflammation of the blood vessels) that mainly affects children. Symptoms … icipants with KD. Studies compared IVIG with ASA, another dose or regimen of IVIG, prednisolone, or infliximab. The majority of studies reported on primary treatment, so those results are reported below. A limited number of studies investigated secondary or tertiary treatment in IVIG-resistant patients. Doses and regimens of IVIG infusion varied between stud …

Immune effector cell-associated enterocolitis post-BCMA directed CAR T-cell therapy: insights from a multicenter case series.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Four steroid-refractory patients were treated with infliximab, of whom 2 (50%) improved to G1. One responder relapsed and achieved improvement with ruxolitinib followed by photopheresis. Another patient received ruxolitinib for 7 days with no improvement. … Despite immunosuppressive therapies—including corticosteroids, infliximab, ruxolitinib, and photopheresis—and nutritional support, responses were limited, with symptoms often persisting for weeks to months. …

Clinical and Laboratory Features of Hemophagocytic Lymphohistiocytosis in People With Disseminated Histoplasmosis.

BACKGROUND: Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening syndrome involving pathologic excitation of the immune system. Disseminated histoplasmosis (DH) is a known trigger of HLH. However, the prevalence of HLH in DH is unknown. Limited data exist on risk factors and outcomes. The goals of this study are to determine the prevalence of HLH among participants with DH at a single center, identify risk factors for HLH in this population, and describe the treatment and outcomes of people with DH and HLH. METHODS: We retrospectively identified cases of DH at our institution from 2

Совпадение в полном тексте источника
… Seven people with autoimmune disease were on a tumor necrosis factor alpha inhibiting biologic agent (adalimumab or infliximab). Figure 1. Selection and exclusion criteria for participants with disseminated histoplasmosis. … dex 20 mg iv QD for 5 days | Etoposide 150 mg/m 2 for 2 doses | Death 13 | 21 | M | AIDS | 5/5 | Pred 40 mg BID for 6 days, HC 100 mg iv Q8 2 days | None | Survival 14 | 41 | F | DLBCL (R-CHOP) | 5/7 | HC 100 mg iv q8 h for 4 days, followed by dex c | IVIG 300 mg/kg | Death 15 | 65 | M | RA (pred, infliximab …

Фармакокинетический, сформированный с помощью модели, дозы Натализумаба в множестве склерозов.

Внутриутробный склероз представляет собой эффективное лечение повторно излучаемого склероза. Однако стандартный 4-недельный интервал лечения для многих пациентов может быть чрезмерным. Продление персональных интервалов с использованием терапевтического контроля за лекарственными средствами может привести к достаточному воздействию наркотиков при одновременном сокращении больничных посещений и расходов на медицинское обслуживание. В этой связи мы изучаем вопрос о том, в какой степени индивидуализированное дозирование по методу TDM может выиграть от дозирования на основе модели (MIPD). Индивидуа

Совпадение в полном тексте источника
… As an example, implementation of MIPD for infliximab in inflammatory bowel disease improved the attainment of the therapeutic target [ 16 ]. A prospective trial with MIPD of infliximab resulted in the reduction of the loss of response compared to conventional dosing [ 17 ]. …

Механизмы и новые регулирующие органы нейроинфламмации: изучение новых терапевтических стратегий в отношении неврологических расстройств.

Нейроинфламмация представляет собой сложную и динамичную реакцию центральной нервной системы (КНС) на травмы, инфекцию и болезни. В то время как острая нейроинфламмация играет защитную роль, облегчая расчистку патогенов и восстановление тканей, хроническая и дисрегулированная воспаление в значительной степени способствует развитию таких нейродегенеративных расстройств, как болезнь Альцгеймера, болезнь Паркинсона и множественный склероз. В рамках этого обзора изучаются клеточные и молекулярные механизмы, лежащие в основе нейроинфламмации, с уделением особого внимания роли микроглий, астроцитов

Совпадение в полном тексте источника
… Anti-TNF drugs such as infliximab and etanercept have shown efficacy in peripheral inflammatory diseases like rheumatoid arthritis, but their efficacy in the CNS has been limited due to poor BBB penetration. … , poor BBB penetration, limited efficacy in chronic conditions. [ 53 , 55 ] Corticosteroids Dexamethasone, Methylprednisolone Suppress NF-κB signaling and promote anti-inflammatory mediators Systemic side effects, limited CNS-specificity, rebound inflammation risk. [ 56 ] Immunomodulators Anti-TNF (Infliximab …

The Effects of Biologics on Hematologic Malignancy Development in Patients with Ankylosing Spondylitis, Psoriasis, or Psoriatic Arthritis: A National Cohort Study.

Biologics are used for ankylosing spondylitis (AS), psoriasis, and psoriatic arthritis (PsA) treatment. The association between biologics and the development of hematologic malignancies is controversial, and data on patients with AS, psoriasis, and PsA are scarce. This retrospective cohort study used data from 2010 to 2020 from Taiwan's National Health Insurance Research Database (NHIRD). Patients with AS, psoriasis, and PsA were divided into a biologics and non biologics group after 1:10 propensity score matching. The hematologic malignancy incidences and the time-/dose-dependent effects on b

Совпадение в полном тексте источника
… Kimball’s study of patients with psoriasis, on the other hand, found no increased risk of lymphoma for the use of TNFi biologics, including etanercept, adalimumab, and infliximab [ 23 ]. … The biologics included TNFi (etanercept, adalimumab, golimumab, infliximab, certolizumab, and opinercept), interleukin-6 (IL-6) inhibitors (tocilizumab), IL-12/23 inhibitors (ustekinumab and guselkumab), IL-17 inhibitors (secukinumab, ixekizumab, and brodalumab), rituximab, abatacept, and vedolizumab …

Active Mycobacterium tuberculosis infection at a comprehensive cancer center, 2006-2014.

BackgroundMorbidity and mortality from Mycobacterium tuberculosis (Mtb) infection remain significant in cancer patients. We evaluated clinical characteristics, management, and outcomes in patients with active Mtb infection at our institution who had cancer or suspicion of cancer.MethodsWe retrospectively examined medical records of all patients with laboratory-confirmed active Mtb infection diagnosed between 2006 and 2014.ResultsA total of 52 patients with laboratory-confirmed active Mtb infection were identified during the study period, resulting in an average rate of 6 new cases per year. Th

Совпадение в полном тексте источника
… treatment for latent Mtb infection, one patient had acute myeloid leukemia and was receiving ruxolitinib at the time of diagnosis; one patient had been referred for suspicion of malignancy and was not receiving any immunosuppressive medications; and one patient had psoriasis for which she received infliximab … of the patients suspected to have malignancy had received corticosteroids within the month prior to presentation for different indications; 1 patient had multiple sclerosis but was not receiving any immunosuppressive therapy at the time of presentation; and 1 patient had psoriasis and had received infliximab …

Relapsing polychondritis: state of the art on clinical practice guidelines.

Due to the rarity of relapsing polychondritis (RP), many unmet needs remain in the management of RP. Here, we present a systematic review of clinical practice guidelines (CPGs) published for RP, as well as a list of the most striking unmet needs for this rare disease. We carried out a systematic search in PubMed and Embase based on controlled terms (medical subject headings and Emtree) and keywords of the disease and publication type (CPGs). The systematic literature review identified 20 citations, among which no CPGs could be identified. We identified 11 main areas with unmet needs in the fie

Совпадение в полном тексте источника
… Cases of necrotising scleritis treated with biologics (infliximab or adalimumab) have also been reported. 10 11 The use of cyanoacrylate glue repairment has been reported for peripheral corneal perforations. 22 The management of respiratory airway involvement depends on its presentation and severity … Severe septicaemia in a patient with polychondritis and sweet's syndrome after initiation of treatment with infliximab. Ann Rheum Dis 2003;62:81–2. 10.1136/ard.62.1.81 …